gsk201204166k2.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending April 2012
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Notification of Transactions of Directors, Persons Discharging
Managerial Responsibility or Connected Persons
The Administrators of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (the "Plan") notified the Company and the under-mentioned persons on 16 April 2012 of an increase in their notional interests in Ordinary Shares and American Depositary Shares (ADSs) at a price of 1408.5 pence per Ordinary Share and $44.97 per ADS following the re-investment of dividends paid to shareholders on 12 April 2012.
|
Sir Andrew Witty
|
Acquisition of 1099 Ordinary Shares under the personal contribution element of the Plan.
|
| |
|
|
Mr S M Bicknell
Mrs D P Connelly
Mr D S Redfern
Dr M M Slaoui
Ms C Thomas
Mr D E Troy
Dr P J T Vallance
|
Acquisition of 1099 Ordinary Shares under the matching element of the Plan (Company contribution).
Acquisition of 129 Ordinary Shares under the personal contribution element of the Plan.
Acquisition of 129 Ordinary Shares under the matching element of the Plan (Company contribution).
Acquisition of 71 ADSs under the personal contribution element of the Plan.
Acquisition of 71 ADSs under the matching element of the Plan (Company contribution).
Acquisition of 145 Ordinary Shares under the personal contribution element of the Plan.
Acquisition of 145 Ordinary Shares under the matching element of the Plan (Company contribution).
Acquisition of 355 ADSs under the personal contribution element of the Plan.
Acquisition of 355 ADSs under the matching element of the Plan (Company contribution).
Acquisition of 32 Ordinary Shares under the personal contribution element of the Plan.
Acquisition of 32 Ordinary Shares under the matching element of the Plan (Company contribution).
Acquisition of 178 ADSs under the personal contribution element of the Plan.
Acquisition of 178 ADSs under the matching element of the Plan (Company contribution).
Acquisition of 288 Ordinary Shares under the personal contribution element of the Plan.
Acquisition of 288 Ordinary Shares under the matching element of the Plan (Company contribution).
|
The notional dividends accrued will be paid out in proportion to the percentage of the participant's deferred annual bonus holdings that will vest following the end of the relevant three year measurement period.
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
16 April 2012
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: April 16, 2012
By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc